Motor Neurone Disease

Department of Health and Social Care written question – answered on 19th April 2018.

Alert me about debates like this

Photo of Tom Brake Tom Brake Liberal Democrat Spokesperson (International Trade), Liberal Democrat Spokesperson (Exiting the European Union)

To ask the Secretary of State for Health and Social Care, pursuant to his Oral Answer of 20 March 2018, Official Report, column 156, on motor neurone disease, which projects received that £52 million investment; and which 24 clinical trials are being recruited to.

Photo of Caroline Dinenage Caroline Dinenage Minister of State (Department of Health and Social Care)

In 2016-17, the National Institute for Health Research (NIHR) invested £52.2 million into health research covered by the ‘Neurological conditions’ category of the UK Health Research Classification System. This £52.2 million was used to fund and support a range of research studies and research infrastructure for neurological conditions and within that, £4.58 million was spent specifically on Motor Neurone Disease (MND) and closely-related conditions.

The NIHR provides the support, expertise and facilities that the NHS needs to undertake world-leading research funded by the NIHR, and other public, charity and life sciences industry partners, by funding a range of infrastructure facilities.

The NIHR Clinical Research Network is currently supporting 19 non-commercial studies and clinical trials on MND and closely-related conditions which are open and recruiting participants. The non-commercial studies are listed in the table below. There are currently two commercial studies which are also recruiting participants.

In 2016-17, the NIHR Research Infrastructure supported 23 studies and trials on MND and closely-related conditions in the NIHR Biomedical Research Centres, Units and other research infrastructure. The majority of these studies have been funded by research charities including the Motor Neurone Disease Association, other research funders and the life sciences industry.

NIHR Clinical Research Network supported Non-Commercial studies on MND and closely-related conditions which are open and recruiting participants


Study Short Name


Trajectories of Outcome in Neurological Conditions Phase 3 Consent and questionnaire


Trajectories of Outcome in Neurological Conditions Phase 2 Demographics and Clinical Info


Motor System Genomics, version 1.0


ALS Biomarkers Study


Tonic 2 Phase 4


MND Register for England, Wales and Northern Ireland


Trajectories of Outcome in Neurological Conditions Phase 1


CSF collection in patients with neurodegenerative diseases


BioMOx Phase 2: The Oxford Study for Biomarkers in Motor Neuron Disease


A Multicentre Biomarker Study in Neurodegeneration


Contributing clinical MRI scans to multi-centre collaboration


Tongue EIM


Using MRI to investigate energy metabolism in MND


Improving support for family and friends caring for people with MND


Serial fasciculation measurements in motor neurone disease


Care Augmentation by Location-linked messaging CALL-Me


MIROCALS_H2020/PHRC-N/2014/GB-01_ID-IL-2_Neuro-Inflammation in ALS Pts


Change in MND


ProSec 3

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.